Educational research platform — not medical or investment advice. Verify all data before decisions.

TERN · NASDAQ

Terns Pharmaceuticals

Oral GLP-1 program (TERN-601) advancing through early obesity trials.

HQ Foster City, CA, USA
Market cap Micro
Focus Oral small-molecule GLP-1
Investor relations ↗
Last updated:Jul 15, 2026Source:SEC EDGAR + company IRVerified:Reviewed against latest filingsData provider:PeptidePlanet Research

Overview

Pipeline programs

2

Active trials

0

Upcoming catalysts

0

Indications

1
Obesity

AI research summary

Generated on demand from verified profile data.

The AI summarizer only sees the verified fields on this page. Every numbered citation maps to a source in the legend below.

Pipeline

0
No peptides linked to this company in our dataset.

Clinical trials

0
No trials linked to this sponsor in our dataset.

Upcoming catalysts

0
No scheduled catalysts on file for this company.

Timeline

Merged approvals, trial milestones, and catalysts. Newest first.

0
No dated events on file.

Verified sources

  1. [1]
    Terns IR — Terns Pharmaceuticalsretrieved 2026-07-15
  2. [2]
    SEC EDGAR — U.S. Securities and Exchange Commissionretrieved 2026-07-15
  3. [3]
    ClinicalTrials.gov — U.S. National Library of Medicineretrieved 2026-07-15

SEC filings search: EDGAR ↗

More companies

LLY

Eli Lilly

Incretin therapies (GLP-1 / GIP / glucagon triagonists)

NVO

Novo Nordisk

GLP-1 analogs, amylin, and combination peptides

AMGN

Amgen

Bispecific peptide antibody conjugates

VKTX

Viking Therapeutics

Dual GLP-1/GIP receptor agonists